Oncobax® AK
Oncology (unspecified)
ResearchActive
Key Facts
About EverImmune
EverImmune is a clinical-stage biotech developing a novel class of cancer treatments based on the gut microbiome. The company's core technology involves identifying and formulating specific bacterial strains or consortia, branded as Oncobax®, which are designed to convert 'cold' tumors responsive to immunotherapy into 'hot' ones. Its lead candidate, Oncobax® AM, is a specific strain of Akkermansia muciniphila being prepared for a Phase 2 trial in non-small cell lung cancer (NSCLC) patients resistant to immunotherapy. EverImmune operates as a private, pre-revenue company advancing a pipeline of live biotherapeutic products through strategic research and planned clinical trials.
View full company profileTherapeutic Areas
Other Oncology (unspecified) Drugs
| Drug | Company | Phase |
|---|---|---|
| Oncology Vaccine Program | CHAIN Biotech | Pre-clinical |
| ARX305 | NovoCodex Biopharmaceuticals | Phase 1 |
| ARX788 | NovoCodex Biopharmaceuticals | Phase 1 |
| Cancer Immunotherapy Nanotherapeutic | Flashpoint Therapeutics | Phase 1 |
| GRWD5769 | Greywolf Therapeutics | Phase 1/2 |
| Platform-derived Program(s) | Immuto Scientific | Discovery/Pre-clinical |
| MBT Oncology Program | Ionic Pharmaceuticals | Pre-clinical |
| ISB 2301 | Ichnos Glenmark Innovation | Preclinical |
| GRC 65327 | Ichnos Glenmark Innovation | Preclinical |
| Platform-Derived Pipeline | Phinomics | Discovery/Pre-clinical |
| Lead Small-Molecule Inhibitor | Eris Biotech | Pre-clinical |
| Orotecan™ | Edison Oncology | Phase 1/2a |